A friend of mine had their insurance deny a growth hormone drug for their son and the endocrinologist insisted it was medically needed. They went to Abvie and Abvie told them that they would give the family the drug for free for one entire year( more if needed). They just had to prove that they did not make more than 100 grand a year.
Most people would think that this would make Abvie less attractive as an investment. I think not.
Recent ABBV News
- Tesla Listed for China’s Government Vehicles; Macy’s Acquisition Offer Raised, and More News • IH Market News • 07/05/2024 12:13:34 PM
- AbbVie to Host Second-Quarter 2024 Earnings Conference Call • PR Newswire (US) • 07/02/2024 12:00:00 PM
- Robert A. Michael Assumes Role as AbbVie Chief Executive Officer • PR Newswire (US) • 07/01/2024 12:00:00 PM
- AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma • PR Newswire (US) • 06/28/2024 06:00:00 AM
- AbbVie Acquires Celsius Therapeutics • PR Newswire (US) • 06/27/2024 01:26:00 PM
- Introducing Allē Payment Plans, Powered by Cherry • PR Newswire (US) • 06/27/2024 12:30:00 PM
- U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma • PR Newswire (US) • 06/26/2024 11:03:00 PM
- AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) • PR Newswire (US) • 06/25/2024 12:15:00 PM
- AbbVie Declares Quarterly Dividend • PR Newswire (US) • 06/21/2024 12:00:00 PM
- AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors • PR Newswire (US) • 06/20/2024 12:00:00 PM
- U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease • PR Newswire (US) • 06/18/2024 10:18:00 PM
- AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer • PR Newswire (US) • 06/14/2024 08:08:00 PM
- AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease • PR Newswire (US) • 06/13/2024 11:59:00 AM
- BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients • PR Newswire (US) • 06/11/2024 12:00:00 PM
- AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer • PR Newswire (US) • 06/06/2024 12:45:00 PM
- SkinMedica® Celebrates 25 Years of Empowering Radiant Skin • PR Newswire (US) • 06/06/2024 12:30:00 PM
- AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers • PR Newswire (US) • 06/06/2024 12:00:00 PM
- AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383 • PR Newswire (US) • 06/05/2024 01:00:00 PM
- RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis • PR Newswire (US) • 06/04/2024 12:30:00 PM
- Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50 • PR Newswire (US) • 06/04/2024 12:05:00 PM
- AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/03/2024 12:30:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/31/2024 08:05:10 PM
- AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis • PR Newswire (US) • 05/31/2024 06:00:00 AM
- AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform • PR Newswire (US) • 05/28/2024 12:00:00 PM
- AbbVie Completes Acquisition of Landos Biopharma • PR Newswire (US) • 05/23/2024 08:05:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM